Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | KMO | O15229 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13414993 | 0.93 | SMN1; SMN2 (0.45) | PARP1DRD3SMN1; SMN2LMNANPC1 | |
| SCHEMBL5423204 | 0.86 | PARP1 (0.49) | PARP1NPC1RAB9AALDH1A1HPGD | |
| SCHEMBL2282510 | 0.84 | KMO (0.56) | PARP1SMN1; SMN2LMNARAB9AALDH1A1 | |
| SCHEMBL6697278 | 0.83 | PARP1 (0.68) | PARP1TDP1 | |
| SCHEMBL13962635 | 0.83 | PARP1 (0.46) | PARP1SMN1; SMN2LMNANPC1RAB9A | |
| SCHEMBL310551 | 0.83 | PARP1 (0.39) | PARP1SMN1; SMN2LMNANPC1RAB9A | |
| SCHEMBL13901589 | 0.83 | PARP1 (0.46) | PARP1NPC1RAB9AALDH1A1KMO | |
| SCHEMBL21153236 | 0.82 | PARP1 (0.43) | PARP1SMN1; SMN2LMNANPC1RAB9A | |
| SCHEMBL9430916 | 0.82 | ATM (0.46) | PARP1DRD3SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL1417028 | 0.82 | RAB9A (0.49) | PARP1SMN1; SMN2LMNANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099367-A1 | Process for preparing a leukotriene antagonist | FARMAPROJECTS, S. A. (ES) | 2009-04-16 | — | — | US | disclosed |
| EP-2004609-A2 | PROCESS FOR PREPARING A LEUKOTRIENE ANTAGONIST | Farmaprojects, S.A. (ES) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007101841-A2 | PROCESS FOR PREPARING A LEUKOTRIENE ANTAGONIST | FARMAPROJECTS, S. A. (ES) | 2007-09-13 | — | — | WO | disclosed |
| EP-1206471-A1 | INTERLEUKIN-5 INHIBITING 6-AZAURACIL DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-05-22 | — | — | EP | disclosed |
| WO-2001010866-A1 | INTERLEUKIN-5 INHIBITING 6-AZAURACIL DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099367-A1 | Process for preparing a leukotriene antagonist | LTC4S, LTB4R2, CYSLTR2 | PARP1 2543/4885DRD3 2711/4885SMN1; SMN2 4033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.